Stereotaxis Announces First MAGiC Procedures in the United States
Stereotaxis, Inc. has successfully performed the first MAGiC procedures in the US using their proprietary robotically-navigated magnetic interventional cardiac ablation catheter, which recently received FDA approval. The MAGiC catheter is designed to treat arrhythmia in patients with complex congenital heart disease and offers improved precision and stability compared to older technology, significantly aiding in complex cases where traditional methods failed.
ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™.